Silva, Gisele Sampaio http://orcid.org/0000-0002-3247-3123
,
Maldonado, Nelson J.
Mejia-Mantilla, Jorge H.
Ortega-Gutierrez, Santiago
Claassen, Jan
Varelas, Panayiotis
Suarez, Jose I.
Funding for this research was provided by:
Universidad San Francisco de Quito
Article History
First Online: 24 July 2019
Conflict of interest
: Dr. Silva reports personal fees from Boehringer Ingelheim, personal fees from BARD, personal fees from Pfizer, Grants from Brazilian Ministry of Health, outside the submitted work. Dr. Maldonado has nothing to disclose. Dr. Mejia-Mantilla has nothing to disclose. Dr. Ortega receives Grants from Siemens, Society of vascular and Interventional Neurology. He is the site PI for 3 endovascular stroke trial at the University of Iowa including TESLA, SEGA and SELECT 2. Dr. Claassen reports Grants from Charles A. Dana Foundation , Grants from James S. McDonnell Foundation, from NIH: The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial, Grants from NIH: I-SPOT, Grants from NIH: Established Status Epilepticus Treatment Trial (ESETT), Grants from Bard: Intrepid, Grants from NIH: Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (I-DEF), Grants from NIH / NLM: BIGDATA: Causal Inference in Large-Scale Time Series with Rare and Latent Events, Grants from NIH: Rhapsody (ZZ-3K3A-201), other from iCE Neurosystems, outside the submitted work. Dr. Varelas reports Grants from Marinus, outside the submitted work. Dr. Suarez reports non-financial support and other from Neurocritical Care Society (President of the Neurocritical Care Society), non-financial support and other from Stroke Journal (member of the Editorial Board of Stroke), non-financial support and other from BARD (Chair of the DSMB for the INTREPID Study), outside the submitted work.
: No ethical approval is required for this type of study.